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General Procedures
All reactions and manipulations were performed under nitrogen or argon, either in a 
Braun Labmaster 100 glovebox or using standard Schlenk-type techniques unless stated 
otherwise. All organic solvents were distilled under nitrogen with the following desiccants: 
sodium-benzophenone-ketyl for diethyl ether, tetrahydrofuran (THF) and 2-
methyltetrahydrofuran (2-Me-THF); sodium for hexanes and toluene; CaH2 for 
dichloromethane, Mg(OMe)2 for methanol. Water used for reactions was demineralized and 
deoxygenated. -Aryl enamides were prepared by Erlenmeyer synthesis.S1 Phosphine-
phosphite (P-OP) ligands 1a, 1d, 1g and 1h and their [Rh(NBD)(P-OP)](BF4) were prepared 
as described previously.S2 All other reagents were purchased from commercial suppliers and 
used as received. NMR spectra were obtained on a Bruker DPX-300, DRX-400, or DRX-500 
spectrometers. 31P{1H} NMR shifts were referenced to external 85% H3PO4, while 13C{1H} 
and 1H shifts were referenced to the residual signals of deuterated solvents. All data are 
reported in ppm downfield from Me4Si. All NMR measurements were carried out at 25 °C, 
unless otherwise stated. GC and HPLC analyses were performed by using a Hewlett-Packard 
Model HP 6890 and Waters 2695 chromatographs with Waters 996 PDA UV detector, 
respectively. HPLC analyses were performed at 30 ºC. Optical rotations were measured on a 
Perkin-Elmer Model 341 polarimeter. ICP and HRMS analyses were carried out by the 
Microanalysis and Mass Spectrometry Services of Universidad de Sevilla at CITIUS, using 
Horiba Jobin Yvon, Ultima 2 spectrometer and JEOL JMS-SX 102A mass spectrometer, 
respectively.
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Synthesis and characterization of new phosphine-phosphite ligands
Ligand 1b
P O P
O
O
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A solution of (S)-3,3’-di-tert-butyl-5,5’,6,6’-tetramethyl-2,2’-bisphenoxyphosphorus chloride 
(0.290 g, 0.69 mmol) and triethylamine (0.2 mL, 1.4 mmol) in toluene (15 mL) was dropwise 
added to a stirred solution of diethylphenolphosphine (0.122 g, 0.67 mmol) in toluene 
(10mL). The resulting mixture was left on stirring overnight, filtered and the solution obtained 
evaporated under vacuum. The oily residue residue produced was dissolved in diethyl ether (5 
mL) and filtered through a short pad of neutral alumina. The solution obtained was evaporated 
under vacuum yielding compound 1b as a white foamy solid (0.314 g, 83 % yield). 1H NMR 
(400 MHz, CD2Cl2): δ = 7.35 (m, 1H, Ar-H), 7.19 (s, 1H, Ar-H), 7.14 (s, 1H, Ar-H), 7.12 (m, 
1H, Ar-H), 7.03 (m, 1H, Ar-H), 6.65 (m, 1H, Ar-H), 2.30 (s, 3H, CH3), 2.26 (s, 3H, CH3), 
1.88 (s, 3H, CH3), 1.84 (s, 3H, CH3), 1.74-1.50 (m, 4H, 2CH2), 1.41 (s, 9H, C(CH3)3), 1.34 (s, 
9H, C(CH3)3), 0.91 (m, 6H, 2CH3). 13C{1H} NMR (101 MHz, CDCl3): δ = 155.4 (d, J(C,P) = 
12 Hz, OCqarom), 154.3 (d, J(C,P) = 6 Hz, OCqarom), 145.0 (d, J(C,P) = 2 Hz, OCqarom), 138.4 
(d, J(C,P) = 3 Hz, Cqarom), 137.7 (s, Cqarom), 135.2 (s, Cqarom), 134.5 (s, Cqarom), 133.3 (d, 
J(C,P) = 11 Hz, CHarom), 132.7 (s, Cqarom), 132.2 (d, J(C,P) = 5 Hz, Cqarom), 131.8 (s, Cqarom), 
131.0 (d, J(C,P) = 3 Hz, Cqarom), 129.5 (s, CHarom), 129.3 (d, J(C,P) = 3 Hz, Cqarom), 128.2 (s, 
CHarom), 127.9 (s, CHarom) , 123.5 (d, J(C,P) = 4 Hz, CHarom), 120.5 (d, J(C,P) = 12 Hz, 
CHarom), 34.9 (s, C(CH3)3), 34.7 (s, C(CH3)3), 31.6 (s, C(CH3)3), 31.3 (d, J(C,P) = 5 Hz, 
C(CH3)3), 20.6 (s, CH3), 20.5 (s, CH3), 18.8 (d, J(C,P) = 12 Hz, CH2), 17.9 (d, J(C,P) = 11 
Hz, CH2), 16.9 (s, CH3), 16.7 (s, CH3), 10.2 (d, , J(C,P) = 15 Hz, CH3), 10.0 (d, , J(C,P) = 13 
Hz, CH3). 31P{1H} NMR (122 MHz, CDCl3): δ = 130.2 (d, J(P,P) = 31 Hz, PO), -22.7 (d, 
J(P,P) = 31 Hz, P). HRMS (FAB): m/z 587.2814, [M+Na]+ (calcd for: C34H46NaO3P2: 
587.2820). [α]D20= +379 (c 0.4, THF).
S4
Ligand 1c
P O P
O
O
S
Compound 1c was synthesized from dicyclohexylphenolphosphine and (S)-3,3’-di-tert-butyl-
5,5’,6,6’-tetramethyl-2,2’-bisphenoxyphosphorus chloride following the procedure described 
for 1b. White foamy solid (0.376 g, 84% yield). 1H NMR (500 MHz, CDCl3): δ = 7.35 (m, 
1H, Ar-H), 7.19 (s, 1H, Ar-H), 7.12 (s, 1H, Ar-H), 7.04 (m, 2H, Ar-H), 6.38 (m, 1H, Ar-H), 
2.31 (s, 3H, CH3), 2.26 (s, 3H, CH3), 1.98-1.43 (m, 12H, cyclohexyl), 1.88 (s, 3H, CH3), 1.85 
(s, 3H, CH3), 1.42 (s, 9H, C(CH3)3), 1.30 (s, 9H, C(CH3)3), 1.30-0.92 (m, 10H, cyclohexyl).
13C{1H} NMR (126 MHz, CDCl3): δ = 156.1 (dd, J(C,P) = 18 Hz, J(C,P) = 4 Hz, OCqarom), 
145.6 (d, J(C,P) = 6 Hz, OCqarom), 145.1 (s, OCqarom), 138.5 (d, J(C,P) = 3 Hz, Cqarom), 137.8 
(s, Cqarom), 135.2 (s, Cqarom), 134.4 (s, Cqarom), 134.0 (s, CHarom), 132.6 (s, Cqarom), 132.3 (d, 
J(C,P) = 6 Hz, Cqarom), 131.7 (s, Cqarom), 131.1 (d, J(C,P) = 3 Hz, Cqarom), 129.4 (s, CHarom), 
128.3 (s, CHarom), 127.9 (s, CHarom), 127.2 (dd, J(C,P) = 22 Hz, J(C,P) = 2 Hz, Cqarom), 123.2 
(s, CHarom), 122.1 (d, J(C,P) = 9 Hz, CHarom), 35.0 (s, C(CH3)3), 34.8 (s, C(CH3)3), 34.2 (d, 
J(C,P) = 15 Hz, PCH), 32.9 (d, J(C,P) = 13 Hz, PCH), 31.6 (s, C(CH3)3 ), 31.3 (d, J(C,P) = 5 
Hz, C(CH3)3), 30.8 (d, J(C,P) = 17 Hz, CH2), 30.3 (d, J(C,P) = 16 Hz, CH2), 29.9 (d, J(C,P) = 
11 Hz, CH2), 28.9 (d, J(C,P) = 6 Hz, CH2), 27.3 (m, 4CH2), 26.6 (d, J(C,P) = 2Hz, 2CH2), 
20.6 (s, 2CH3), 16.9 (s, CH3), 16.7 (s, CH3). 31P{1H} NMR (162 MHz, CDCl3): δ = 122.0 (d, 
J(P,P) = 42 Hz, PO), -14.4 (d, J(P,P) = 42 Hz, P). HRMS (EI): m/z 673.3950, [M+H]+ (calcd 
for C42H59O3P2: 673.3939). [α]D20= +381 (c 0.2, THF).
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An ampoule was charged with (2-hydroxyphenyl)diphenylphosphonium bromide (0.120 g, 
0.33 mmol), (S)-3,3’-di-methyl-2,2’-bisnaphtoxyphosphorus chloride (0.127 g, 0.33 mmol)S3 
and ScavengePore phenethyldiethylamine resin (Rapp Polymere, resin capacity 0.74mmol/g; 
1.35 g, 1.0 mmol,). Dichloromethane was added (10 mL) and reaction mixture was shaken for 
12 h using orbital stirrer. Solvent was removed under vacuum and residue was extracted with 
diethyl ether (5 x 5mL). Solution was concentrated and filtered through short pad of neutral 
alumina. Solvent was removed and ligand 1e was isolated as a white foamy solid (0.175 g, 
85% yield). 1H NMR (500 MHz, C6D6): δ = 7.60 (dd, J(H,H) = 8.0 Hz, 2.5Hz, 2H, Ar-H), 
7.47-7.44 (m, 3H, Ar-H), 7.36 (m, 2H, Ar-H), 7.32-7.29 (m, 2H, Ar-H), 7.19-7.16 (m, 5H, Ar-
H), 7.02-6.89 (m, 9H, Ar-H), 6.73 (t, J(H,H) = 7.4 Hz, 1H, Ar-H), 2.57(s, 3H, CH3), 2.36 (s, 
3H, CH3). 13C{1H} NMR (101 MHz, CD2Cl2): δ = 154.7 (d, J(C,P) = 7 Hz, OCqarom), 154.5 
(d, J(C,P) = 6 Hz, OCqarom), 148.0 (d, J(C,P) = 6 Hz, OCqarom), 146.5 (d, J(C,P) = 3 Hz, 
Cqarom), 136.5 (d, J(C,P) = 7 Hz, Cqarom), 136.4 (d, J(C,P) = 7 Hz, Cqarom), 134.8 (s, CHarom), 
134.6 (s, CHarom), 134.4 (s, CHarom), 134.2 (s, CHarom), 134.0 (s, CHarom), 132.0 (m, Cqarom), 
131.6 (m, Cqarom), 130.8 (s, Cqarom), 130.7 (s, 2CHarom), 130.3 (s, CHarom), 130.1 (d, J(C,P) = 3 
Hz, Cqarom), 130.0 (s, CHarom), 129.3 (s, CHarom), 129.1 (s, CHarom), 128.9 (s, 2CHarom), 128.8 
(s, 2CHarom), 128.8 (s, Cqarom), 128.0 (s, CHarom), 127.9 (s, CHarom), 127.1 (s, CHarom), 127.0 
(s, CHarom), 125.7 (s, CHarom), 125.6 (d, J(C,P) = 2 Hz, 2CHarom), 125.3 (s, CHarom), 125.1 (s, 
CHarom), 125.0 (d, J(C,P) = 6 Hz, Cqarom), 122.9 (d, J(C,P) = 2 Hz, Cqarom), 120.1 (dd, J(C,P) 
= 12 Hz, 1 Hz, Cqarom), 18.3 (d, J(C,P) = 4 Hz, CH3), 17.7 (s, CH3). 31P{1H} NMR (202 MHz, 
C6D6): δ = 139.5 (d, J(P, P) = 19 Hz, PO), -17.3 (d, J(P, P) = 19 Hz, PC). HRMS (ESI): m/z 
621.1728, [M+H]+ (calcd for C40H31O3P2: 621.1743). [α]D20= +245 (c 0.7, THF).
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A solution of (S)-5,5’,6,6’,7,7’,8,8’-octahydro-2,2’-bisnaphtoxyphosphorus chloride (0.499 g, 
1.39 mmol)S3 and triethylamine (0.79 mL, 5.6 mmol) in methylene chloride (15 mL) was 
dropwise added to a stirred solution of (2-hydroxyphenyl)diphenylphosphonium bromide 
(0.500 g, 1.39 mmol) in methylene chloride (10 mL). Mixture was left stirring overnight. 
Solution was brought to dryness. Oily residue was extracted with diethyl ether (3 x 5 mL) and 
filtered through to another Schlenk tube. Solvent was removed under vacuum and oily 
product was washed with hexane (3 x 5mL). Oil residue was dissolved in diethyl ether (5 mL) 
and brought to dryness. Ligand 1f was obtained as white foamy solid (0.409 g, 49% yield). 1H 
NMR (500 MHz, CD2Cl2): δ = 7.44-7.30 (m, 10H, Ar-H), 7.27-7.23 (m, 1H, Ar-H), 7.20-7.14 
(m, 2H, Ar-H), 7.09-7.06 (m, 2H, Ar-H), 6.97-6.93 (m, 1H, Ar-H), 6.88-6.85 (m, 1H, Ar-H), 
6.77-6.73 (m, 1H, Ar-H), 2.80 (m, 4H, CH2), 2.62 (m, 2H, CH2), 2.27-2.20 (m, 2H, CH2), 
1.79 (m, 5H, CH2), 1.56 (m, 3H, CH2). 13C{1H} NMR (101 MHz, CD2Cl2): δ = 154.3 (dd, 
J(C,P) = 18, 8 Hz, OCqarom), 146.1 (s, OCqarom), 146.0 (d, J(C,P) = 6 Hz, OCqarom), 139.0 (s, 
Cqarom), 138.0 (s, Cqarom), 136.4 (d, J(C,P) = 9 Hz, Cqarom), 136.3 (d, J(C,P) = 9 Hz, Cqarom), 
135.6 (s, Cqarom), 134.8 (s, Cqarom), 134.7 (s, CHarom), 134.6 (s, CHarom), 134.5 (s, CHarom), 
134.4 (s, CHarom), 134.3 (s, CHarom), 133.9 (d, J(C,P) = 19 Hz, CHarom), 130.7 (d, J(C,P) = 3 
Hz, Cqarom), 130.6 (s, CHarom), 129.8 (s, CHarom), 129.7 (d, J(C,P) = 5 Hz, Cqarom), 129.6 (s, 
CHarom), 129.4 (s, CHarom), 129.0 (s, 2CHarom), 128.9 (s, 2CHarom), 128.1 (d, J(C,P) = 2 Hz, 
Cqarom), 125.1 (s, CHarom), 120.4 (d, J(C,P) = 10 Hz, CHarom), 119.2 (s, 2CHarom), 29.5 (s, 
2CH2), 28.2 (s, 2CH2), 23.1 (s, CH2), 23.0 (s, CH2), 22.9 (s, CH2), 22.8 (s, CH2). 31P{1H} 
NMR (202 MHz, CD2Cl2): δ = 135.2 (d, J(P, P) = 14 Hz, PO), -17.0 (d, J(P, P) = 14 Hz, PC). 
HRMS (EI): m/z 601.2035, [M+H]+ (calcd for C38H35O3P2: 601.2056). [α]D20= +39 (c 0.6, 
THF).
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Synthesis and characterization of [Rh(NBD)(P-OP)]BF4 complexes
[Rh(NBD)(1b)](BF4)
A solution of 1b (0.220 g, 0.390 mmol) in methylene chloride (10 mL) was added dropwise to 
a stirred solution of [Rh(NBD)2](BF4) (0.145 g, 0.390 mmol) in methylene chloride (5 mL). A 
colour change from dark red to orange was observed in the solution. Reaction mixture was 
stirred for two hours, concentrated to 5mL and filtered. Solvent was partially evaporated and 
diethyl ether (25 mL) was added dropwise, producing an orange precipitate. The mixture was 
filtered, the solid collected, washed with diethyl ether (3 x 5mL) and dried under vacuum. 
Title product was isolated as orange powder (0.258 g, 77 % yield). 1H NMR (400 MHz, 
CD2Cl2): δ = 7.48 (t, J(H,H) = 7.5 Hz, 1H, Ar-H), 7.43-7.35 (m, 2H, Ar-H), 7.33 (s, 1H, Ar-
H), 7.32 (s, 1H, Ar-H), 6.87 (m, 1H, Ar-H), 6.04 (brs, 1H, =CH NBD), 5.76 (brs, 1H, =CH 
NBD), 5.67 (brs, 1H, =CH NBD), 4.18 (brs, 1H, CH NBD), 3.98 (brs, 1H, CH NBD), 3.84 
(brs, 1H, =CH NBD), 2.42-2.34 (m, 1H, PCH2), 2.32 (s, 3H, CH3), 2.31 (s, 3H, CH3), 2.33 (s, 
3H, CH3), 2.20-1.98 (m, 2H, CH2), 1.86 (s, 3H, CH3), 1.78 (s, 3H, CH3),1.77 (m, 2H, CH2 
NBD), 1.72 (m, 1H, PCH2), 1.50 (s, 9H, C(CH3)3), 1.36 (s, 9H, C(CH3)3), 1.18 (m, 6H, 
2CH2). 13C{1H} NMR (101 MHz, CD2Cl2): δ = 155.1 (dd, J(C,Rh) = 9 Hz, J(C,P) = 4 Hz, 
OCqarom), 144.9 (dd, J(C,Rh) = 14 Hz, J(C,P) = 1 Hz, OCqarom), 143.6 (d, J(C,P) = 6 Hz, 
OCqarom), 137.8 (d, J(C,P) = 4 Hz, Cqarom), 137.5 (d, J(C,P) = 2 Hz, Cqarom), 136.9 (d, J(C,P) 
= 2 Hz, Cqarom), 135.7 (d, J(C,P) = 2 Hz, Cqarom), 135.1 (d, J(C,P) = 2 Hz, Cqarom), 134.4 (d, 
J(C,P) = 4 Hz, Cqarom), 133.8 (s, CHarom), 130.9(s, CHarom), 130.3 (d, J(C,P) = 3 Hz, Cqarom), 
129.6 (d, J(C,P) = 2 Hz, CHarom), 129.4 (d, J(C,P) = 1 Hz, CHarom), 129.3 (d, J(C,P) = 3 Hz, 
Cqarom), 126.7 (dd, J(C,Rh) = 6 Hz, J(C,P) = 2 Hz, CHarom) 123.2 (dd, J(C,Rh) = 4 Hz, J(C,P) 
= 2 Hz, CHarom), 116.0 (dd, J(C,Rh) = 43 Hz, J(C,P) = 8 Hz, PCqarom), 97.9 (dd, J(C,Rh) = 12 
Hz, J(C,P) = 2 Hz, =CH NBD), 96.9 (dd, J(C,Rh) = 15 Hz, J(C,P) = 5 Hz, =CH NBD), 92.1 
(td, J(C,Rh) = 7 Hz, J(C,P) = 2 Hz, =CH NBD), 79.8 (ddd, J(C,Rh) = 10 Hz, J(C,P) = 6 Hz, 
J(C,P) = 3 Hz, =CH NBD), 72.0 (m, CH2 NBD), 56.0 (m, CH NBD), 55.4 (m, CH NBD), 
35.5 (s, C(CH3)3), 35.3 (s, C(CH3)3), 31.9 (s, C(CH3)3), 32.0 (d, J(C,P) = 4 Hz, CH2), 31.8 (s, 
C(CH3)3), 24.1 (d, J(C,P) = 30 Hz, PCH2), 31.0 (d, J(C,P) = 6 Hz, CH2), 20.6 (s, Ar-CH3), 
20.5 (s, Ar-CH3), 16.8 (s, 2Ar-CH3), 16.8 (s, CH3), 15.6 (d, J(C,P) = 28 Hz, PCH2), 9.7 (m, 
CH3), 9.2 (s, CH3). 31P{1H} NMR (162 MHz, CD2Cl2): δ = 131.7 (dd, J(P, Rh) = 280 Hz, J(P, 
P) = 67 Hz, PO), 10.5 (dd, J(P, Rh) = 143 Hz, J(P, P) = 66 Hz, PC). Elemental analysis: 
calculated: C 58.17 %, H 6.43 %, found: C 58.45 %, H 6.49 %.
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Complex [Rh(NBD)(1c)](BF4)
This complex was obtained as an orange powder according procedure described above for 
[Rh(NBD)(1b)](BF4) (0.282 g, 85% yield). 1H NMR (400 MHz, CD2Cl2): δ = 7.46 (t, J(H,H) 
= 7.5 Hz, 1H, Ar-H), 7.39-7.34 (m, 2H, Ar-H), 7.34 (s, 1H, Ar-H), 7.31 (s, 1H, Ar-H), 6.83 
(m, 1H, Ar-H), 6.28 (brs, 1H, =CH NBD), 6.05 (brs, 1H, =CH NBD), 5.67 (brs, 1H, =CH 
NBD), 4.16 (brs, 1H, CH NBD), 3.95 (brs, 1H, CH NBD), 3.58 (brs, 1H, =CH NBD), 2.67 
(m, 1H, PCH2), 2.50 (m, 1H, CH2 Cy), 2.32 (s, 3H, CH3), 2.30 (s, 3H, CH3), 2.28 (m, 1H, 
PCH), 1.97-1.66 (m, 10H, CH2 Cy), 1.83 (s, 3H, CH3), 1.79 (m, 2H, CH2 NBD), 1.76 (s, 3H, 
CH3), 1.50 (s, 9H, C(CH3)3), 1.45-1.20 (m, 6H, CH2 Cy), 1.36 (s, 9H, C(CH3)3), 1.09-0.95 (m, 
3H, 2CH2 Cy). 13C{1H} NMR (101 MHz, CD2Cl2): δ = 155.1 (dd, J(C,Rh) = 9 Hz, J(C,P) = 4 
Hz, OCqarom), 144.9 (dd, J(C,Rh) = 14 Hz, J(C,P) = 1 Hz, OCqarom), 143.7 (d, J(C,P) = 6 Hz, 
OCqarom), 137.8 (d, J(C,P) = 4 Hz, Cqarom), 137.5 (d, J(C,P) = 3 Hz, Cqarom), 137.0 (d, J(C,P) 
= 2 Hz, Cqarom), 135.8 (d, J(C,P) = 2 Hz, Cqarom), 135.2 (d, J(C,P) = 2 Hz, Cqarom), 134.5 (d, 
J(C,P) = 2 Hz, Cqarom), 133.6 (s, CHarom), 131.8 (s, CHarom), 130.0 (d, J(C,P) = 3 Hz, Cqarom), 
129.7 (d, J(C,P) = 2 Hz, CHarom), 129.5 (d, J(C,P) = 1 Hz, CHarom), 129.3 (d, J(C,P) = 3 Hz, 
Cqarom), 126.4 (dd, J(C,Rh) = 5 Hz, J(C,P) = 2 Hz, CHarom) 123.8 (dd, J(C,Rh) = 4 Hz, J(C,P) 
= 2 Hz, CHarom), 114.9 (dd, J(C,Rh) = 37 Hz, J(C,P) = 8 Hz, PCqarom), 99.4 (dd, J(C,Rh) = 14 
Hz, J(C,P) = 4 Hz, =CH NBD), 96.2 (dd, J(C,Rh) = 13 Hz, J(C,P) = 5 Hz, =CH NBD), 89.7 
(m, =CH NBD), 75.1 (ddd, J(C,Rh) = 11 Hz, J(C,P) = 6 Hz, J(C,P) = 2 Hz, =CH NBD), 71.9 
(brs, CH2 NBD), 55.5 (s, CH NBD), 55.0 (m, CH NBD), 38.7 (d, J(C,P) = 23 Hz, PCH), 35.5 
(s, C(CH3)3), 35.3 (s, C(CH3)3), 32.8 (d, J(C,P) = 22 Hz, PCH), 32.4 (s, CH2), 32.2 (s, 
C(CH3)3), 31.7 (s, C(CH3)3), 30.3 (d, J(C,P) = 4 Hz, CH2), 28.8 (d, J(C,P) = 4 Hz, CH2), 27.7 
(d, J(C,P) = 14 Hz, CH2), 27.2 (d, J(C,P) = 5 Hz, CH2), 27.1 (d, J(C,P) = 7 Hz, CH2), 26.9 (d, 
J(C,P) = 2 Hz, CH2), 26.7 (d, J(C,P) = 4 Hz, CH2), 26.4 (d, J(C,P) = 1 Hz, CH2), 26.1 (d, 
J(C,P) = 1 Hz, CH2), 20.6 (s, CH3), 20.5 (s, CH3), 16.8 (s, CH3), 16.7 (s, CH3). 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = 132.0 (dd, J(P, Rh) = 281 Hz, J(P, P) = 59 Hz, PO), 12.6 (dd, J(P, 
Rh) = 144 Hz, J(P, P) = 59 Hz, PC). Elemental analysis: calculated: C 61.64%, H 6.97%, 
found: C 61.74%, H 6.81%.
Complex [Rh(NBD)(1e)](BF4)
This complex was obtained as an orange powder according procedure described above for 
[Rh(NBD)(1b)](BF4) (0.173 g, 85 % yield). 1H NMR (400 MHz, CDCl3): δ = 8.04 (s, 1H, Ar-
H), 7.96-7.93 (m, 3H, Ar-H), 7.68-7.54 (m, 5H, Ar-H), 7.51-7.41 (m, 5H, Ar-H), 7.30-7.19 
(m, 4H, Ar-H), 7.13 (d, J(H,H) = 8.2 Hz, 1H, Ar-H), 7.08 (m, 1H, Ar-H), 6.91 (m, 1H, Ar-H), 
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5.81 (brs, 2H, =CH NBD), 5.69 (brs, 1H, =CH NBD), 4.62 (brs, 1H, =CH NBD), 4.17 (brs, 
1H, CH NBD), 4.14 (brs, 1H, CH NBD), 2.71 (s, 3H, Ar-CH3), 2.46 (s, 3H, Ar-CH3), 1.71 
(m, 2H, CH2 NBD). 13C{1H} NMR (101 MHz, CD2Cl2): δ = 155.3 (d, J(C, P) = 11 Hz, 
OCqarom), 146.9 (d, J(C, P) = 12 Hz, OCqarom), 145.9 (d, J(C, P) = 6 Hz, OCqarom), 134.9 (s, 
CHarom), 133.9 (s, CHarom), 133.9 (s, CHarom), 133.8 (s, CHarom), 133.6 (s, CHarom), 133.5 (s, 
CHarom), 132.8 (t, J(C, P) = 2 Hz, 2CHarom), 132.2 (s, 2Cqarom), 131.7 (dd, J(C, P) = 18, 2 Hz, 
2Cqarom), 131.4 (s, CHarom), 131.3 (s, CHarom), 130.3 (dd, J(C, P) = 11, 3 Hz, 4CHarom), 129.5 
(d, J(C, P) = 3Hz, Cqarom), 129.2 (d, J(C, P) = 1 Hz, Cqarom), 128.4 (s, CHarom), 128.2 (s, 
CHarom), 127.3 (s, CHarom), 127.1 (d, J(C, P) = 9 Hz, Cqarom), 127.0 (s, CHarom), 126.7 (s, 
CHarom), 126.6 (d, J(C, P) = 2 Hz, 2CHarom), 126.5 (s, Cqarom), 126.4 (s, 2CHarom), 123.6 (d, 
J(C, P) = 2 Hz, Cqarom), 122.7 (t, J(C, P) = 4 Hz, CHarom ), 122.4 (d, J(C, P) = 3 Hz, Cqarom), 
116.3 (dd, J(C, P) = 52, 9 Hz, Cqarom), 104.6 (brs, =CH NBD), 104.1 (brs, =CH NBD) 95.5 
(brs, =CH NBD), 88.5 (brs, =CH NBD), 73.5 (s, CH2 NBD), 56.5 (s, CH NBD), 56.1 (s, CH 
NBD), 19.0 (s, CH3), 17.7 (s, CH3). 31P{1H} NMR (202 MHz, CD2Cl2): δ = 139.0 (dd, J(P, 
Rh) = 281 Hz, J(P, P) = 71Hz, PO), 16.7 (dd, J(P, Rh) = 142 Hz, J(P, P) = 71 Hz, PC). 
Elemental analysis: calculated: C 62.55%, H 4.24%, found: C 62.59%, H 4.05%.
Complex [Rh(NBD)(1f)]BF4
This complex was obtained as an orange powder according procedure described above for 
[Rh(NBD)(1b)](BF4) (0.521 g, 68% yield). 1H NMR (500 MHz, CD2Cl2): δ = 7.65-7.57 (m, 
9H, Ar-H), 7.38-7.36 (m, 1H, Ar-H), 7.32-7.29 (m, 2H, Ar-H), 7.21-7.16 (m, 2H, Ar-H), 7.05 
(m, 1H, Ar-H), 6.89 (d, J(H, H) = 8.3 Hz, 1H, Ar-H), 5.74 (brs, 1H, =CH NBD), 5.65 (brs, 
1H, =CH NBD), 5.55 (brs, 1H, =CH NBD), 4.78 (brs, 1H, =CH NBD), 4.13 (brs, 2H, CH 
NBD), 2.90-2.79 (m, 4H, CH2), 2.69-2.58 (m, 2H, CH2), 2.27 (m, 1H, CH2), 2.15 (m, 1H, 
CH2), 1.79 (m, 6H, CH2), 1.79 (m, 2H, CH2 NBD), 1.59-1.42 (m, 2H, CH2). 13C{1H} NMR 
(101 MHz, CD2Cl2): δ = 155.3 (d, J(C, P) = 11 Hz, OCqarom), 145.7 (dd, J(C, P) = 12, 1 Hz, 
OCqarom), 145.2 (d, J(C, P) = 5 Hz, OCqarom), 140.1 (d, J(C, P) = 2 Hz, Cqarom), 139.1 (d, J(C, 
P) = 2 Hz, Cqarom), 137.4 (d, J(C, P) = 2 Hz, Cqarom), 136.7 (d, J(C, P) = 2 Hz, Cqarom), 134.8 
(s, CHarom), 134.7 (s, CHarom), 134.6 (s, CHarom), 133.5 (d, J(C, P) = 3 Hz, CHarom), 133.3 (s, 
CHarom), 133.2 (s, CHarom), 133.1 (d, J(C, P) = 3 Hz, CHarom), 132.4 (d, J(C, P) = 3 Hz, 
CHarom), 130.5 (d, J(C, P) = 1 Hz, CHarom), 130.4 (d, J(C, P) = 2 Hz, CHarom), 130.2 (d, J(C, P) 
= 3 Hz, CHarom), 130.1 (s, CHarom), 130.1 (s, CHarom), 130.0 (s, CHarom), 127.7 (dd, J(C, Rh) = 
53, 2 Hz, J(C, P) = 2 Hz, Cqarom), 127.6 (d, J(C, P) = 2 Hz, Cqarom), 126.8 (d, J(C, P) = 2 
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Hz,Cqarom), 126.3 (d, J(C, P) = 49 Hz, Cqarom), 126.2 (dd, J(C, P) = 7, 1 Hz, CHarom), 122.5 (t, 
J(C, P) = 5 Hz, CHarom), 119.1 (d, J(C, P) = 4 Hz, CHarom), 118.3 (d, J(C, P) = 2 Hz, CHarom), 
116.9 (dd, J(C, Rh) = 52 Hz, J(C, P) = 9 Hz, Cqarom), 103.5 (m, =CH NBD), 102.8 (m, =CH 
NBD), 93.8 (m, =CH NBD), 91.65 (m, =CH NBD), 73.1 (s, CH2 NBD), 56.4 (s, CH NBD), 
55.8 (s, CH NBD), 29.5 (s, CH2), 29.4 (s, CH2), 28.1 (s, CH2), 28.0 (s, CH2), 22.8 (s, CH2), 
22.7 (s, CH2), 22.6 (s, CH2), 22.6(s, CH2).
31P{1H} NMR (202 MHz, CD2Cl2): δ = 132.5 (dd, J(P, Rh) = 280 Hz, J(P, P) = 73 Hz, PO), 
17.8 (dd, J(P, Rh) = 142 Hz, J(P, P) = 73 Hz, PC). Elemental analysis: calculated: C 61.25%, 
H 4.80%, found: C 61.20%, H 4.68%.
Preparation of supported complexes
Preparation of Li-resin
According to a previously described procedure,S4 commercial Dowex® 50WX2-100 in its H+ 
form (10 g) was washed with distilled water (10 x 50 mL). Washings initially orange became 
colourless. Resin was sequentially washed with methanol (5 x 50 mL), THF (3 x 50 mL), 
dichloromethane (2 x 50 mL), methanol (2 x 50 mL) and diethyl ether (3x50ml). Resin was 
finally dried using vacuum/argon cycles and left overnight under vacuum. Dry resin (9 g) was 
placed in a round-bottom flask and water was added (150 mL). Suspension was stirred for 5 
minutes using orbital shaker, water was removed and 1 M solution of LiOH in water (360 
mL) was slowly poured. The resulting mixture was left stirring for 15 minutes and supernatant 
removed by filtration. The resin was repeatedly washed with small portions of distilled water 
until neutral pH of washings was observed. Resin was then washed with methanol (5x50mL), 
diethyl ether (3x50mL), dried using vacuum/argon cycles and finally left under vacuum 
overnight. Product obtained as creamy white resin was stored in a glovebox.
General procedure for the immobilization of [Rh(diolefin)(P-OP)](BF4) complexes
Supported complexes were prepared by interaction of solutions of title compounds with the 
Li-resin as exemplified below for 3a. Li-resin (0.459 g, 2.21 mEq) was placed in a round-
bottom Schlenk flask, degassed and methanol (10 mL) was added. Solution 3a (0.063 g, 0.067 
mmol) in methanol (5 mL) was added dropwise to a stirred suspension of the resin. Mixture 
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was stirred for 12 hours at room temperature and resin was filtered off using a thin cannula. 
Resin was washed with methanol (5 x 5mL), THF (3 x 5mL), diethyl ether (3 x 5 mL), dried 
using vacuum/argon cycles and left under vacuum overnight. Product 3a was obtained as 
orange resin beads. ICP analysis of the mineralized resin (see mineralization procedure 
below) showed a rhodium content of 0.79 % w/w, what accounts for 61 % immobilization of 
the catalyst precursor. Corresponding data for other supported complexes are detailed below: 
2d, 1.10 % Rh, 83 % immobilization; 3b, 0.92 % Rh, 68 % immobilization; 3c, 0.87 % Rh, 66 
% immobilization; 3e, 1.16 % Rh, 87 % immobilization; 3f, 1.09 % Rh, 81 % immobilization; 
3g, 1.06 % Rh, 80 % immobilization; 3h, 0.91 % Rh, 74 % immobilization.
Procedures for asymmetric hydrogenation 
Hydrogenations with supported catalyts performed in a parallel reactor
In a glovebox a suitable amount of supported catalyst (typically 5.0 mg) and corresponding 
amount of substrate 4a-4j were placed in an HPLC vial. Small stirring bar was placed inside 
the vial and it was closed with a screw cap equipped with with PTFE septum. Vial was taken 
out of the glovebox and degassed water (1 mL) was injected into the vial. Vial was placed in a 
HEL CAT-18 reactor and small syringe needle was placed in the septum. The reactor was 
quickly closed and purged thoroughly with nitrogen, placed in an oil bath and heated to 
desired temperature. Reactor was then purged with hydrogen and pressurized at 4 bar of 
hydrogen and left magnetically stirred for suitable time. Then, the reactor was depressurized 
and the resulting suspension (or biphasic system composed by product and aqueous phases) or 
solution (reactions in MeOH) was separated from resin beads and brought to dryness. 
Conversion was determined by 1H NMR analysis on the resulting residue. The latter was then 
dissolved in ethyl acetate/hexane 1:10 mixture and passed through a short pad of silica to 
remove catalyst impurities. The solution obtained was carefully evaporated and the residue 
obtained was analyzed by chiral chromatography to determine enantiomeric excess. 
Configuration for 5a and 5b was determined as described before.S6 For products 5c-5j 
configuration has been assigned by analogy to that observed in hydrogenations of 5a and 5b.
Hydrogenations with supported catalysts performed in a glass reactor (2-6 mL)
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These reactions were run in a way similar to described above, with the exception that a Büchi 
miniclave 50 mL glass reactor was used.
Hydrogenations with supported catalysts performed in 2-Me-THF/H2O (conditions A) 
or in Triton-X100/H2O mixtures (conditions B)
These reactions were run in a way similar to described above either using a 2-Me-THF/H2O 
(1:9) mixture or aqueous solutions of Triton-X100 of suitable concentration as solvents.
Hydrogenations with [Rh(NBD)(P-OP)](BF4) complexes
In a glovebox suitable amount of catalyst (typically 1.0 mg) was placed in an HPLC vial as a 
solution in CH2Cl2. Solvent was evaporated under vacuum and the appropriate amount of 
substrate was added. Vial was closed and 1 mL of water was injected into the vial. Vial was 
placed in a HEL CAT-18 reactor and small syringe needle was placed in the septum. The 
reactor was closed and purged with nitrogen. Reactor was pressurized to 4 bar with hydrogen 
and left stirring for 24h. Reactor was depressurized; solution was brought to dryness and 
residue was analyzed in order to determine conversion and enantioselectivity.
Recycling experiments:
Catalyst recycling in hydrogenation of 4a
In a glove-box Büchi miniclave 50 mL glass reactor was charged with supported catalyst and 
substrate. Reactor was closed and taken out from the glovebox and suitable amount of solvent 
was injected through a port with a gas-tight syringe. Reactor was flushed with hydrogen with 
five pressurization (2 bar)/depressurization cycles and pressurized to 4bar. Reaction mixture 
was stirred for the desired time. Stirring was stopped and supernatant was separated from the 
catalyst using gas-tight syringe equipped with a long needle of bore diameter smaller than size 
of a resin bead. Reactor was fed with a solution of 4a. Small pressure drop was observed due 
to manipulations so vessel was repressurized with hydrogen to 4 bars and stirring was started. 
Reaction mixture was again stirred over the time dependant on a length of the cycle.
Catalyst recycling in hydrogenation of 4f in water
These experiments were performed using the system schematically drawn in the following 
diagram. It is composed by a Büchi miniclave 50 mL glass reactor with ports for hydrogen 
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and introduction of solvent/extraction of reaction suspension and a third port including an 
antechamber for introduction of solid 4f. The latter was packed inside a small piece of Teflon 
tubing (ca. 1.5 mm inner diameter). The procedure was analogous to that described above for 
4a, with the exception that substrate for the second and following cycles was added in solid 
form through the antechamber limited by two ball valves.
Antechamber
H2 Inlet
Solvent/
sample port
Piece of Teflon tubing
containing solid 4f
Determination of Rh leaching
For the determination of Rh leaching in reactions two procedures were used. First includes 
mineralization as follows. After hydrogenation, resin beads were separated from reaction 
mixture and the liquid phase obtained evaporated to dryness. An aliquot of the solid residue 
(typically 20 mg) was introduced in a microwave-heated digestión bomb and concentrated 
nitric acid (8 mL, 65 %) and H2O2 (1 mL, 30 %) were added, the mixture was heated at 200 
ºC for 15 minutes, then cooled down to room temperature. Reactor was washed with distilled 
water, and solution finally diluted up to 25 mL with distilled water. The solution obtained was 
then analyzed by ICP. The experimentally determined detection limit for Rh using this 
procedure was 0.017 ppm. For reactions performed in water, samples for ICP analysis were 
alternatively prepared by taken part of the aqueous phase of the reaction mixture and diluted 
up to 5 mL with HNO3 (65 %). For this procedure the detection limit experimentally 
determined was 0.047 ppm. In the case of reactions performed in 1-2 mL of water, 
supernatant was separated from resin beads and the latter washed with additional water finally 
obtaining 3.0 mL of solution. Of the resulting solution, a measured aliquot (1.5-2.5 mL) was 
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taken for ICP analysis. For reactions prepared with 6.0 mL of water (entries S14 and S15) the 
aliquot for analysis was obtained by taking 5.0 mL of the reaction mixture and concentrating 
it under reduced pressure down to 2 mL. For the recycling experiment (entries S16-S20) an 
aliquot of 1.0 mL was taken directly from the reaction mixture.
Table S1. Rh leaching values obtained in representative hydrogenation reactions
Entry Entry/
Tablea
Sample 
prepb
Rh total 
(mg)c
Rh leached 
(mg)
% Rh leached [Rh] (ppm)
S1 1/1 M 0.039 0.0047 12.0 1.6
S2 7/1 M 0.055 0.0084 15.3 2.8
S3 1/2 M 0.039 0.0035 9.0 3.5
S4 2/2 M 0.055 0.0100 18.2 10.0
S5 13/3 D 0.035 <0.0003 <0.8 <0.3
S6 14/3 D 0.035 <0.0003 <0.8 <0.3
S7 3/4 D 0.058 <0.0005 <0.9 <0.2
S8 4/4 D 0.058 0.0014 2.4 0.7
S9 6/4 D 0.058 <0.0005 <0.9 <0.2
S10 7/4 D 0.058 <0.0005 <0.9 <0.2
S11 9/4 D 0.058 0.0012 2.0 0.6
S12 6/5 D 0.058 <0.0003 <0.5 <0.3
S14 10/5 D 0.058 <0.0003 <0.5 <0.05
S15 11/5 D 0.058 <0.0003 <0.5 <0.05
S16 22/6 D 0.070 <0.0014 <2.0 <0.2
S17 23/6 D 0.070 <0.0014 <2.0 <0.2
S18 24/6 D 0.070 <0.0014 <2.0 <0.2
S19 25/6 D 0.070 <0.0014 <2.0 <0.2
a Entry and Table in the main text. b Procedure used for the preparation of the ICP sample (D 
= dilution, M = mineralization). c Rh amount used in the reaction. d Calculated [Rh] (ppm) in 
the reaction medium.
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Separation conditions for products 5a-5j
Racemic mixtures for HPLC analysis were obtained by hydrogenation of substrates 4a-4j 
with achiral catalyst [Rh(COD)(DiPFc)](BF4) [DiPFc = 1,1’-
bis(diisopropylphosphino)ferrocene] in CH2Cl2. Below are detailed the separation conditions 
for 5a-5j:
Methyl 2-acetamidopropanoate (5a):S5 GC, , 150°C isotherm, β-dex 30m, 0.7mL/min, t1 = 
8.3 min (R), t2 = 8.7 min (S).
Methyl 2-acetamido-3-phenylpropanoate (5b):S5 HPLC, Chiralcel OD-H, 90:10 n-
hexane:iPrOH, flow 1.0 mL/min, t1 = 10.1 min (R), t2 = 12.6 min (S).
Methyl 2-acetamido-3-(p-tolyl)propanoate (5c):S6 HPLC, Chiralcel OD-H, 90:10 n-
hexane:iPrOH, flow 1.0 mL/min, t1 = 9.4 min (R), t2 = 11.4 min (S).
Methyl 2-acetamido-3-(m-tolyl)propanoate (5d):S7 HPLC, Chiralcel OD-H, 90:10 n-
hexane:iPrOH, flow 1.0 mL/min, t1 = 11.9 min (R), t2 = 14.5 min (S).
Methyl 2-acetamido-3-(4-methoxyphenyl)propanoate (5e):S6 HPLC, Chiralcel OD-H, 
90:10 n-hexane:iPrOH, flow 1.0 mL/min, t1 = 19.6 min (R), t2 = 23.0 min (S).
Methyl 2-acetamido-3-(3-methoxyphenyl)propanoate (5f):S8 HPLC, Chiralcel OD-H, 
90:10 n-hexane:iPrOH, flow 1.0 mL/min, t1 = 16.8 min (R), t2 = 21.0 min (S).
Methyl 2-acetamido-3-(3,4-dimethoxyphenyl)propanoate (5g):S1a HPLC, Chiralcel AD-H, 
85:15 n-hexane:iPrOH, flow 1.0 mL/min, t1 = 15.2 min (R), t2 = 16.4 min (S).
Methyl 2-acetamido-3-(4-fluorophenyl)propanoate (5h):S6 HPLC, Chiralcel OD-H, 90:10 
n-hexane:iPrOH, flow 1.0 mL/min, t1 = 14.0 min (R), t2 = 17.5 min (S).
Methyl 2-acetamido-3-(4-bromophenyl)propanoate (5i):S8 HPLC, Chiralcel OD-H, 90:10 
n-hexane:iPrOH, flow 1.0 mL/min, t1 = 14.5 min (R), t2 = 19.6 min (S).
Methyl 2-acetamido-3-(3-bromophenyl)propanoate (5j):S9 HPLC, Chiralcel OD-H, 90:10 
n-hexane:iPrOH, flow 1.0 mL/min, t1 = 14.1 min (R), t2 = 16.7 min (S).
Gel-phase NMR studies
Sample was prepared by placing 3g (100 mg, 5.8 µmol Rh) in a heavy wall NMR Sample 
Tube equipped with a Teflon valve and slowly adding dry CD3OD (1mL). Subsequent 
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hydrogenation was studied by pressurizing at 4 bar of H2, while for the formation of enamide 
adducts the tube was depressurized and the proper amount of 4a or 4b was added under 
nitrogen. All 31P{1H} NMR spectra were acquired using standard pulse program.
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Figure S1. 1H NMR (CDCl3, 400 MHz) spectrum of 1b
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Figure S2. 13C{1H} NMR (CDCl3, 101 MHz) spectrum of 1b
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Figure S3. 31P{1H} NMR (CDCl3, 162 MHz) spectrum of 1b
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Figure S4. 1H NMR (CDCl3, 500 MHz) spectrum of 1c
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Figure S5. 13C{1H} NMR (CDCl3, 127 MHz) spectrum of 1c
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Figure S6. 31P{1H} NMR (CDCl3, 162 MHz) spectrum of 1c
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Figure S7. 1H NMR (CDCl3, 500 MHz) spectrum of 1d
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Figure S8. 13C{1H} NMR (CDCl3, 101 MHz) spectrum of 1d
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Figure S9. 31P{1H} NMR (CDCl3, 202 MHz) spectrum of 1d
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Figure S10. 1H NMR (CD2Cl2, 500 MHz) spectrum of 1f
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Figure S11. 13C{1H} NMR (CD2Cl2, 101 MHz) spectrum of 1f
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Figure S12. 31P{1H} NMR (CD2Cl2, 202 MHz) spectrum of 1f
S29
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
(ppm)
6.
16
8.
87
9.
00
2.
91
9.
00
3.
07
2.
11
5.
93
1.
05
0.
94
0.
96
0.
97
0.
95
0.
97
0.
95
0.
91
1.
91
2.
05
1.
03
0.
09
1.
18
1.
36
1.
50
1.
72
1.
78
1.
86
1.
98
2.
20
2.
31
2.
32
2.
34
2.
42
3.
84
3.
98
4.
18
5.
67
5.
76
6.
04
6.
87
7.
32
7.
33
7.
35
7.
43
7.
48
Figure S13. 1H NMR (CD2Cl2, 400 MHz) spectrum of [Rh(1b)(NBD)]BF4
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Figure S14. 13C{1H} NMR (CD2Cl2, 101 MHz) spectrum of [Rh(1b)(NBD)]BF4
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Figure S15. 31P{1H} NMR (CD2Cl2, 162 MHz) spectrum of [Rh(1b)(NBD)]BF4
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Figure S16. 1H NMR (CD2Cl2, 400 MHz) spectrum of [Rh(1c)(NBD)]BF4
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Figure S17. 13C{1H} NMR (CD2Cl2, 101 MHz) spectrum of [Rh(1c)(NBD)]BF4
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Figure S18. 31P{1H} NMR (CD2Cl2, 162 MHz) spectrum of [Rh(1c)(NBD)]BF4
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Figure S19. 1H NMR (CD2Cl2, 500 MHz) spectrum of [Rh(1e)(NBD)]BF4
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Figure S20. 13C{1H} NMR (CD2Cl2, 400 MHz) spectrum of [Rh(1e)(NBD)]BF4
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Figure S21. 31P{1H} NMR (CD2Cl2, 121.5 MHz) spectrum of [Rh(1e)(NBD)]BF4
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Figure S22. 1H NMR (CD2Cl2, 500 MHz) spectrum of [Rh(1f)(NBD)]BF4
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Figure S23. 13C{1H} NMR (CD2Cl2, 101 MHz) spectrum of [Rh(1f)(NBD)]BF4
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Figure S24. 31P{1H} NMR (CD2Cl2, 400 MHz) spectrum of [Rh(1f)(NBD)]BF4
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Figure S25. Gel-phase 31P{1H} NMR spectra (162 MHz, CD3OD) of complex 3g
S42
Figure S26. Gel-phase 31P{1H} NMR spectra (162 MHz, CD3OD) of complex 3g pressurized under 4 bar H2.
S43
Figure S27. Gel-phase 31P{1H} NMR spectra (162 MHz, CD3OD) of complex 3g after pressurizing with 4 bar H2 and addition of 12 equiv. of 4b
S44
Figure S29. Gel-phase 31P{1H} NMR spectra (162 MHz, CD3OD) of complex 3g regenerated after addition of NBD (12 equiv)
S45
Enantiomeric excess determination of methyl 2-acetamidopropanoate (5a)
(rac)- (5a)
(R)- (5a)
S46
Enantiomeric excess determination of methyl 2-acetamido-3-phenylpropanoate (5b)
(rac)- (5b)
(R)- (5b)
S47
Enantiomeric excess determination of methyl 2-acetamido-3-(4-methylphenyl)propanoate (5c)
(rac)- (5c)
(R)- (5c)
S48
Enantiomeric excess determination of methyl 2-acetamido-3-(3-methylphenyl)propanoate (5d)
(rac)- (5d)
(R)- (5d)
S49
Enantiomeric excess determination of methyl 2-acetamido-3-(4-methoxyphenyl)propanoate (5e)
(rac)- (5e)
(R)- (5e)
S50
Enantiomeric excess determination of methyl 2-acetamido-3-(3-methoxyphenyl)propanoate (5f)
(rac)- (5f)
(R)- (5f)
S51
Enantiomeric excess determination of methyl 2-acetamido-3-(3,4-dimethoxyphenyl)propanoate (5g)
(rac)- (5g)
(R)- (5g)
S52
Enantiomeric excess determination of methyl 2-acetamido-3-(4-fluorophenyl)propanoate (5h)
(rac)- (5h)
(R)- (5h)
S53
Enantiomeric excess determination of methyl 2-acetamido-3-(4-bromophenyl)propanoate (5i)
(rac)- (5i)
(R)- (5i)
S54
Enantiomeric excess determination of methyl 2-acetamido-3-(3-bromophenyl)propanoate (5j)
(rac)- (5j)
(R)- (5j)
